Nutriband (NTRB) announced that it has signed an addendum to the Commercial Development and Clinical Supply Agreement for its lead product, Aversa Fentanyl, that it has in place with its partner, Kindeva Drug Delivery, a global contract development and manufacturing organization, CDMO, focused on drug-device combination products. Nutriband and Kindeva have revised their agreement to formalize their exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments. Nutriband is partnering with Kindeva Drug Delivery to develop Aversa Fentanyl which combines Nutriband’s Aversa abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue